CurifyLabs, a Finnish health technology company, has secured €12 million in a Series A funding round. The company builds automated platforms for compounding personalised medicines, aiming to make customised treatments more scalable and accessible.
The round will fuel expansion into the United States and accelerate development of its core platform. No lead investor or valuation details were disclosed in the source.
The personalised medicine market is growing rapidly as healthcare shifts toward tailored treatments. CurifyLabs faces competition from other automation-focused firms, but its focus on pharmacy compounding—where dosages are custom-mixed—is a niche with high regulatory hurdles.
This funding signals continued investor appetite for technologies that bridge pharmaceutical manufacturing and digital health. If successful, CurifyLabs could streamline a traditionally manual process, reducing errors and enabling more precise care.
No comment from the company or its investors was included in the source. The company was founded in Helsinki and focuses on software and hardware for dose personalisation.
Counterargument: Automated compounding must overcome stringent regulatory frameworks in each market, which could slow US expansion and limit near-term revenue. Building trust with pharmacists and regulators will be critical.